K. Ray-Chaudhuri

Identifying and characterizing non-motor fluctuations in PD 2:54
Identifying and characterizing non-motor fluctuations in PD
K. Ray-Chaudhuri • 17 Sep 2022
Investigations into managing non-motor fluctuations 2:33
Investigations into managing non-motor fluctuations
K. Ray-Chaudhuri • 17 Sep 2022
Wellness and holistic health in Parkinson’s disease 2:30
Wellness and holistic health in Parkinson’s disease
K. Ray-Chaudhuri • 17 Sep 2022
Update on OCEAN and OASIS: Opicapone for pain & sleep disorders in PD 1:32
Update on OCEAN and OASIS: Opicapone for pain & sleep disorders in PD
K. Ray-Chaudhuri • 17 Sep 2022
Managing the vital 5 of Parkinson’s disease 3:24
Managing the vital 5 of Parkinson’s disease
K. Ray-Chaudhuri • 27 Jun 2022
Interim results of SC foslevodopa/foscarbidopa in Parkinson’s disease 1:18
Interim results of SC foslevodopa/foscarbidopa in Parkinson’s disease
K. Ray-Chaudhuri • 27 Jun 2022
Opicapone for pain in PD: the OCEAN study 2:13
Opicapone for pain in PD: the OCEAN study
K. Ray-Chaudhuri • 27 Jun 2022
The ELEGANCE study: levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease 1:13
The ELEGANCE study: levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease
K. Ray-Chaudhuri • 27 Jun 2022
Final results of DUOGLOBE: real-world evidence for LGIC in advanced Parkinson’s disease 1:33
Final results of DUOGLOBE: real-world evidence for LGIC in advanced Parkinson’s disease
K. Ray-Chaudhuri • 27 Jun 2022
Unmet needs in Parkinson’s disease 2:31
Unmet needs in Parkinson’s disease
K. Ray-Chaudhuri • 29 May 2020
The potential role of metformin in the treatment of Parkinson’s disease 5:18
The potential role of metformin in the treatment of Parkinson’s disease
K. Ray-Chaudhuri • 29 May 2020
The content of VJNeurology is intended for healthcare professionals